The patient, 23 year old female, with the Zosteriform Porokeratosis on right side of trunk and extrimity and a superimposed Disseminated Superficial Actinic Porokeratosis on face, was treated at Dept. of Dermatology, Catholic Medical College. The lesions appeared at the age of 7. Her mother had similar lesions on the face and extrimities. 3% 5-Fluorouracil in Vanishing cream base was applied topically under occlusive dressing for 40 days, and the dressing was changed every 24 hours. On seventh day erythema and papular lesion appeared, and oral administration of steroid and intermittent topical betamethasone dressing was enable to continued the occlusive dressing. One year after the treatment the lesion did not recurred and shallow atropic scar were left with normal skin color.
Administration, Oral ; Bandages ; Betamethasone ; Cicatrix ; Dermatology ; Erythema ; Female ; Fluorouracil* ; Humans ; Mothers ; Occlusive Dressings ; Porokeratosis* ; Skin ; Young Adult

This survey was to elucidate the bacterial clearance time (BCT) among the patient of L-type and B-group leprosy who had been und.er chernotherapy and foll- ow up with bacterial examination 4 times every year more than 3 years at the Chronic Disease Laboratory of Catholic Medical College. The 99 patients, 53 L-type and 46 B-group, were slected for this study. These patients were classified again into 2 groups: 80 patients with negative bacterial index and 19 patient of posit.ive bacterial index. The patient with negative bacterial index was subdivided into 3 groups by BCT. 1. Rapid decrease group (RA group) BCT<(4years) 2. Standard decrease group (ST group) 4BCT<7 R. Slow decrease group (SL group) 7.
Chronic Disease ; Drug Therapy* ; Humans ; Leprosy* ; Leprosy, Borderline* ; Leprosy, Lepromatous* ; Prognosis*

The aims of study presented here were to determine dose-dependent effects of UVB irradiation on CHS reaction and comparative effects of VVB on the induction and elicitation in guinea pigs. Pre-induction exposure to either suberythemal or supraerythemal doses of UVB resulted in suppreasion of CHS (53.47% & 57.64%) campared to positive control (79. 86%) However, suberythemal doses of UVB generated a more potent suppression than supraerythemal doses. Pre-elicitation exposure to suberythemal doses of UVB on the elicitation sites and adjacent to elicitation sites resulted in suppressed CHS reactions in both groups (60.4zg & 56.25p,). When the reaction by UVB was eliminated from the cutaneous reaction elicited in guinea pigs sensitized to DNCB, by UVB irradiation on the adjacent to elicitation sites, generated a more potent suppression than that UVB was directly irradiated on the elicitation sites.
Animals ; Dermatitis, Contact* ; Dinitrochlorobenzene* ; Guinea Pigs* ; Guinea*

The aim of this study was to evaluate the preventive role of epigallocatechin-3 gallate (EGCG, a derivative of green tea) in ischemia/reperfusion (I/R) injury of isolated rat hearts. It has been suggested that EGCG has beneficial health effects, including prevention of cancer and heart disease, and it is also a potent antioxidant. Rat hearts were subjected to 20 min of normoxia, 20 min of zero-flow ischemia and then 50 min of reperfusion. EGCG was perfused 10 min before ischemia and during the whole reperfusion period. EGCG significantly increased left ventricular developed pressure (LVDP) and increased maximum positive and negative dP/dt (+/-dP/dtmax). EGCG also significantly increased the coronary flow (CF) at baseline before ischemia and at the onset of the reperfusion period. Moreover, EGCG decreased left ventricular end diastolic pressure (LVEDP). This study showed that lipid peroxydation was inhibited and Mn-SOD and catalase expressions were increased in the presence of EGCG. In addition, EGCG increased levels of Bcl-2, Mn-superoxide dismutase (SOD), and catalase expression and decreased levels of Bax and increased the ratio of Bcl-2/Bax in isolated rat hearts. Cleaved caspase-3 was decreased after EGCG treatment. EGCG markedly decreased the infarct size while attenuating the increase in lactate dehydrogenase (LDH) levels in the effluent. In summary, we suggest that EGCG has a protective effect on I/R-associated hemodynamic alteration and injury by acting as an antioxidant and anti-apoptotic agent in one.
Animals ; Apoptosis ; Blood Pressure ; Caspase 3 ; Catalase ; Heart ; Heart Diseases ; Hemodynamics ; Ischemia ; L-Lactate Dehydrogenase ; Rats ; Reperfusion ; Superoxide Dismutase

BACKGROUND: Cyclosporine (CSA) plus 4 doses of methotrexate (MTX) is the commonly used regimen for GVHD prophylaxis. It has been previously found that the omission of the day +11 dose of MTX was associated with an increased risk of acute GVHD in the allogeneic BMT setting. However, little is known about its impact in the PBSCT setting. METHODS: Of the 68 patients, 30 patients (44%) received 4 doses of MTX (the MTX4 group), while 38 patients (56%) received less than 4 doses (the MTX3 group) because of their severe mucositis, hepatic dysfunction or renal failure. RESULTS: The cumulative incidence of acute GVHD was 60% in the MTX4 and 86% in the MTX3 group (P=0.038), while that of grade III and IV acute GVHD was 7% in the MTX4 group and 39% in the MTX3 group (P=0.017). Of the 61 patients evaluated for chronic GVHD, the cumulative incidence of chronic GVHD was 54% in the MTX4 group and 97% in the MTX3 group (P=0.001), while that of extensive chronic GVHD was 26% in the MTX4 group and 63% in the MTX3 group (P=0.004). There were no differences in the overall survival and the incidence of relapse between the two groups. On multivariate analyses, MTX3 was a poor prognostic factor in terms of acute GVHD and extensive chronic GVHD. CONCLUSION: This study suggested that omitting day +11 MTX and the clinical situation of the MTX3 group seemed to be associated with an increased incidence of acute and chronic GVHD. Accordingly, administration of day +11 MTX accompanied by active treatment of mucositis may prevent GVHD in the allogeneic PBSCT setting, but we need to conduct a large scale prospective study.
Cyclosporine ; Graft vs Host Disease* ; Humans ; Incidence* ; Methotrexate* ; Mucositis ; Multivariate Analysis ; Peripheral Blood Stem Cell Transplantation* ; Recurrence ; Renal Insufficiency